How NIA Membership Opened the Door for InFinite Biotech to Shape the Future of Nanomaterial Risk Assessment

At the May 2026 meeting of the ECHA’s Nanomaterial Expert Group (NMEG), NIA Member Infinite Biotech presented a novel “in-vitro-learned digital twin” platform (InFinite™) designed to predict long-term health effects of nanomaterial exposure using advanced New Approach Methodologies (NAMs) and digital modelling. The platform combines live cellular monitoring, mechanistic modelling, and in silico disease evolution to generate rapid predictions of long-term toxicity while potentially reducing animal testing and regulatory costs. The system has already been pre-validated against more than 4,400 in vivo datasets covering 49 materials and demonstrated predictive accuracy for inflammation and LOAEL determination in inhalation-related studies. InFinite highlights potential future applications for grouping, read-across, workplace assessment, and integrated approaches to testing and assessment (IATA) for nanomaterials.